These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11590538)

  • 1. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response.
    Boufassa F; Dulioust A; Lascaux AS; Meyer L; Boué F; Delfraissy JF; Sobel A; Goujard C
    HIV Clin Trials; 2001; 2(4):339-45. PubMed ID: 11590538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study.
    Cames C; Pascal L; Ba A; Mbodj H; Ouattara B; Diallo NF; Msellati P; Mbaye N; Sy Signate H; Blanche S; Diack A;
    BMC Infect Dis; 2018 Aug; 18(1):374. PubMed ID: 30081838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-reported signs of lipodystrophy by persons living with HIV infection.
    Dreezen C; Schrooten W; de Mey I; Goebel FD; Dedes N; Florence E; Colebunders R;
    Int J STD AIDS; 2002 Jun; 13(6):393-8. PubMed ID: 12015013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
    Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
    Martinez E; Mocroft A; García-Viejo MA; Pérez-Cuevas JB; Blanco JL; Mallolas J; Bianchi L; Conget I; Blanch J; Phillips A; Gatell JM
    Lancet; 2001 Feb; 357(9256):592-8. PubMed ID: 11558485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch to efavirenz in a protease inhibitor-containing regimen.
    Knechten H; Stürner KH; Höhn C; Braun P
    HIV Clin Trials; 2001; 2(3):200-4. PubMed ID: 11590528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine.
    Thiébaut R; Daucourt V; Mercié P; Ekouévi DK; Malvy D; Morlat P; Dupon M; Neau D; Farbos S; Marimoutou C; Dabis F
    Clin Infect Dis; 2000 Dec; 31(6):1482-7. PubMed ID: 11096016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
    Brinkman K; Smeitink JA; Romijn JA; Reiss P
    Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil.
    Ceccato MG; Bonolo PF; Souza Neto AI; Araújo FS; Freitas MI
    Braz J Med Biol Res; 2011 Nov; 44(11):1177-83. PubMed ID: 22052375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in rural South India.
    Kalyanasundaram AP; Jacob SM; Hemalatha R; Sivakumar MR
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(5):329-34. PubMed ID: 21508297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.